RPI 4610

Drug Profile

RPI 4610

Alternative Names: Angiozyme; Cancer ribozyme therapy

Latest Information Update: 09 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirna Therapeutics
  • Developer Chiron Corporation; Sirna Therapeutics
  • Class Antineoplastics; Ribozymes
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Solid tumours

Most Recent Events

  • 09 Aug 2004 Discontinued - Phase-II for Breast cancer in USA (SC)
  • 09 Aug 2004 Discontinued - Phase-II for Colorectal cancer in USA (SC)
  • 09 Aug 2004 Discontinued - Phase-II for Solid tumours in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top